Nektar begins investigator-sponsored trial of etirinotecan pegol
06:24 EDT 8 Aug 2012 | Pharmaceutical Business Review
Nektar Therapeutics has begun an investigator-sponsored trial evaluating etirinotecan pegol (NKTR-102), a targeted topoisomerase I inhibitor, in patients with bevacizumab (avastin)-resistant high-grade.
Original Article: Nektar begins investigator-sponsored trial of etirinotecan pegol
More From BioPortfolio on "Nektar begins investigator-sponsored trial of etirinotecan pegol"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
